secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0000950170-24-084254
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx aligns with FDA on Phase 3 design for GTX-102 in Angelman syndrome
-----------------------------------------------------------------------------

- FDA alignment on EoP2 meeting for GTX-102; Phase 3 trial to enroll ~120 UBE3A deletion patients.
- Primary endpoint: Bayley-4 cognitive raw score; 48-week double-blind, sham-controlled design.
- Patients in control arm eligible to roll over to treatment after double-blind period.
- EMA accepted Phase 3 design under PRIME; PMDA meeting expected in coming weeks.
- Plans for open-label study to evaluate GTX-102 in other Angelman genotypes and age groups.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024084254/0000950170-24-084254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024084254/rare-20240717.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-084254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer